Biogen’s Spinraza Stays Ahead Of Novartis And Roche Challengers In SMA – For Now
Evrysdi Growing Fast
Executive Summary
Biogen is hoping to stem the decline in its blockbuster’s revenues but Novartis’ Zolgensma and Roche’s Evrysdi look hard to stop.